Home › Funds › FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND › VRTX

FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND reported holding 139,893 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$73.1M, representing 0.38% of its reported portfolio and ranking #45 among its reported holdings. FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND has disclosed VRTX holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)139.89K sh
Reported value held$73.14M
Portfolio Weight0.38%
First reportedQ3 2023
Last changeReduce
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND's VRTX position evolved

FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND first disclosed a stake in VRTX in Q3 2023 at 71,488 shares (US$24.9M). The position peaked in Q2 2026 at 148,682 shares, worth US$73.9M. Across 12 filings, FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 139,893 shares valued at US$73.1M — a reduction of -8,789 shares quarter over quarter.. Notable position changes include a 68% increase in Q1 2026 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 71.49K $24.86M New
Q4 2023 68.99K $28.07M Reduce
Q1 2024 70.99K $29.67M Add
Q3 2024 71.99K $33.48M Add
Q4 2024 68.09K $27.42M Reduce
Q1 2025 73.89K $35.82M Add
Q2 2025 91.09K $40.55M Add
Q3 2025 89.62K $35.10M Reduce
Q4 2025 89.06K $40.38M Reduce
Q1 2026 149.96K $66.96M Add
Q2 2026 148.68K $73.85M Reduce
Q3 2026 139.89K $73.14M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND held VRTX?

FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND has disclosed VRTX holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

What is FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND's current position in VRTX?

As of Q3 2026, FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND holds 139.89K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $73.14M, representing 0.38% of its reported portfolio and ranking #45.

Has FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND been buying or selling VRTX?

In the latest 13F filing (Q3 2026), FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND reduced its position in VRTX. The position peaked in Q2 2026 at 148.68K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.